| 2.81 0.11 (4.07%) | 11-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.68 |
1-year : | 4.06 |
| Resists | First : | 3.15 |
Second : | 3.47 |
| Pivot price | 3.05 |
|||
| Supports | First : | 2.63 |
Second : | 2.18 |
| MAs | MA(5) : | 2.84 |
MA(20) : | 3.05 |
| MA(100) : | 2.58 |
MA(250) : | 1.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 14.9 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 7.13 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PROK ] has closed above bottom band by 19.1%. Bollinger Bands are 53% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.96 - 2.99 | 2.99 - 3 |
| Low: | 2.64 - 2.68 | 2.68 - 2.7 |
| Close: | 2.66 - 2.72 | 2.72 - 2.75 |
Thu, 06 Nov 2025
ProKidney Corp. Reports Positive Phase 2 Results for Rilparencel in Advanced Chronic Kidney Disease and Diabetes - Quiver Quantitative
Wed, 05 Nov 2025
ProKidney (PROK) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Tue, 04 Nov 2025
ProKidney (NASDAQ:PROK) Stock Price Down 9% - Time to Sell? - MarketBeat
Tue, 04 Nov 2025
ProKidney Corp.'s (NASDAQ:PROK) Last Week's 11% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake - 富途牛牛
Wed, 29 Oct 2025
ProKidney (Nasdaq: PROK) Nov 12 Guggenheim chat webcast; to join Jefferies meetings - Stock Titan
Mon, 20 Oct 2025
ProKidney Announces Two Abstracts Selected for Presentation - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 136 (M) |
| Held by Insiders | 8.672e+007 (%) |
| Held by Institutions | 26.6 (%) |
| Shares Short | 10,120 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7019e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -17 % |
| Return on Assets (ttm) | 967.8 % |
| Return on Equity (ttm) | -25.3 % |
| Qtrly Rev. Growth | 527000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -22.89 |
| EBITDA (p.s.) | 297740 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.13 |
| Price to Cash Flow | -0.67 |
| Dividend | 0 |
| Forward Dividend | 1.074e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|